Disruptive Psychopharmacology
Boris D. Heifets, Robert C. Malenka
JAMA Psychiatry June 26, 2019 DOI: 10.1001/jamapsychiatry.2019.1145 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychopharmacology Methamphetamine Hallucinogen Psychotherapist |
| Citations | 28 |
| Key points | MDMA and psilocybin have potential therapeutic utility, but their clinical use requires development of mental health care infrastructures. |
Abstract
This Viewpoint discusses the potential therapeutic utility of methylenedioxy-methamphetamine and psilocybin and outlines mental health care infrastructures that would need to be put in place should these drugs be approved for treatment.